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A B S T R A C T   
Nuclear factor erythroid 2-related factor 2 (Nrf2) has dual effects on inflammation and cancer progression 
depending on the microenvironment. Estrogens have a protective effect on colorectal cancer (CRC) development. 
The aim of this study was to investigate CRC development in Nrf2 knockout (KO) mice. Azoxymethane (AOM) 
and dextran sulfate sodium (DSS)-treated wild-type (WT) and Nrf2 KO male mice were sacrificed at weeks 2 and 
16 after AOM injection with/without 17β-estradiol (E2) treatment during week 1. Disease activity index and 
colon tissue damage at week 2 showed strong attenuation following E2 administration in WT mice but to a lesser 
extent in Nrf2 KO male mice. At week 16, E2 significantly diminished AOM/DSS-induced adenoma/cancer 
incidence at distal colon in the Nrf2 KO group, but not in the WT. Furthermore, mRNA or protein levels of NF-κB- 
related mediators (i.e., iNOS, TNF-α, and IL-1β) and Nrf2-related antioxidants (i.e., NQO1 and HO-1) were 
significantly lower in the Nrf2 KO group regardless of E2 treatment compared to the WT. The expression of 
estrogen receptor beta (ERβ) was higher in the Nrf2 KO group than in the WT. In conclusion, estrogen further 
inhibits CRC by upregulating ERβ-related alternate pathways in the absence of Nrf2.   
1. Introduction 
Colorectal cancer (CRC) is estimated to be the third leading cause of 
cancer-related death in the United States in 2020 [1]. In Korea, the 
incidence rate of CRC is higher in men than in women in all age groups, 
although CRC remains a main cause of death in elderly women over 65 
years of age [2]. Generally, colon tumors develop more frequently in 
men than in women [3], and CRC shows sex-specific differences 
worldwide [4]. Azoxymethane (AOM) and dextran sulfate sodium (DSS) 
treatments [5–7] are the most widely used protocols for the establish-
ment of animal models of colon carcinogenesis [8–10] because they 
result in the well-developed multistep colon carcinogenesis based on the 
aberrant crypt foci (ACF)-adenoma-carcinoma sequence with the rele-
vant molecular alterations [9]. Nuclear factor erythroid 2-related factor 
2 (Nrf2) is a transcription factor that consists of a basic leucine zipper 
protein that regulates adaptive cellular defense mechanism in response 
to various stimuli such as oxidative, proteotoxic, and metabolic stresses 
as well as inflammation [11,12]. Under stress conditions, Nrf2 becomes 
dissociated from Kelch-like ECH-associated protein 1 (KEAP1, a nega-
tive regulator of Nrf2 in the cytoplasm), followed by translocation into 
the nucleus [11], binds to a consensus antioxidant response element 
(ARE) binding sequence (5′-TGACnnnGC-3′), and regulates antioxidant 
and phase II carcinogen detoxifying enzymes, such as heme oxygenase-1 
(HO-1), nicotinamide adenine dinucleotide phosphate: quinone dehy-
drogenase 1 (NQO1), glutamate-cysteine ligase catalytic subunit 
(GCLC), and glutamate-cysteine ligase modifier subunit (GCLM) [13]. 
The activation of these enzymes maintains cellular homeostasis, and 
exerts anti-inflammatory and anti-tumorigenic activity [14,15]. 
Furthermore, anti-inflammatory mechanisms of Nrf2 include suppres-
sion of lipopolysaccharide (LPS)-induced expression of proinflammatory 
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cytokines such as Interleukin (IL)-6 and IL-1β [16], and reduction of 
DSS-induced expression of proinflammatory cytokines such as tumor 
necrosis factor-alpha (TNF-α) and IL-6 through blocking of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling 
[17]. 
Recently, emerging evidences have revealed the dual effect of Nrf2 as 
anti-carcinogenic and pro-carcinogenic. Activated Nrf2 not only protects 
normal cells from transforming into cancer cells, but also promotes the 
survival of cancer cells under detrimental conditions [18,19]. In addi-
tion, meta-analysis showed that cancer patients with high Nrf2 expres-
sion exhibit worse clinical outcomes compared to patients with low Nrf2 
expression [20]. Nrf2 overexpression is associated with chemotherapy 
resistance in many cancers including gastric cancer [21]. Furthermore, 
overexpression of HO-1 and NQO1 (Nrf2 target genes) has been reported 
in prostate [22] and colon cancers [23], respectively. Nrf2 KO (Nrf2− /− ) 
and WT (Nrf2+/+) male and female AOM/DSS mouse models represent a 
useful tool to clarify the role of Nrf2 in colitis and CRC development. 
The protective role of estrogen in colon carcinogenesis [24,25], 
neurodegenerative diseases [26], and cardiovascular diseases [27] has 
been reported in both males and females. The administration of 17β- 
estradiol (E2) in an ovariectomized retinal degeneration model reduces 
reactive oxygen species (ROS) production through Nrf2 activation 
mediated by the PI3K/AKT- and estrogen receptor (ER)-dependent 
pathways [28]. In addition, phytoestrogens (such as resveratrol and 
quercetin) and ER agonists (such as genistein) modulate the activity of 
NF-κB and Nrf2 [29]. Resveratrol induces P53 expression and cleavage 
Fig. 1. Selection of Nrf2 KO mice using genotyping 
and a schematic illustration of the experiment. (A) 
Heterogeneous Nrf2 KO (Nrf2+/− ) male and female 
mice were mated and then homogeneous Nrf2 KO 
(Nrf2− /− ) male and female mice were selected. (B) 
Genotyping of WT and Nrf2 KO mice. Representa-
tive agarose gel showing the PCR products. Nrf2 WT 
allele produces a 262-bp band, whereas the targeted 
allele produces a 214-bp band. Heterogeneous Nrf2 
KO allele produces both, 214-bp and 262-bp bands. 
(C) Experimental scheme. WT and Nrf2 KO male 
mice were used in the AOM/DSS-induced colitis- 
associated CRC protocol. AOM (10 mg/kg) was 
injected to the mice on Day 0. One week after, DSS 
(2.5%) was provided in the drinking water for one 
week. E2 (10 mg/kg) was administrated by daily 
intraperitoneal injection for one week during DSS 
treatment. The mice were sacrificed at week 2 and 
16 after AOM injection. ♂, male; ♀, female; +/+ and 
WT, wild-type; +/- and het, heterogeneous 
knockout; -/- and KO, homogeneous knockout; 
AOM, azoxymethane; DSS, dextran sodium sulfate; 
E2, 17β-estradiol.   
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of PARP in an Nrf2-dependent manner in MCF-7 breast cancer cells [30]. 
We previously reported that E2 (10 mg/kg) suppresses the initiation of 
CRC by activating Nrf2 in AOM/DSS-treated male mice although Nrf2 
promotes CRC at the tumorigenesis stage [31]. In addition, E2 (10 nM) 
showed anti-inflammatory effects by inhibiting NF-κB and COX-2, and 
by increasing antioxidant proteins in TNF-α-treated CCD841CoN cells, 
originating from normal human female epithelial cells [32]. We further 
verified the role of E2 (10 nM) as anti-inflammatory agent through 
activation of Nrf2 in mouse embryonic fibroblasts (MEF). In WT MEFs, 
E2 (10 nM) inhibited TNF-α-induced nuclear translocation of NF-κB and 
the expression of its target protein inducible Nitric Oxide Synthase 
(iNOS). However, its effect was diminished in Nrf2 KO MEFs [33]. Based 
on these data, we hypothesized that the anti-CRC activity of E2 may be 
altered in the absence of Nrf2. To validate the hypothesis, we investi-
gated the development of colitis and colitis-associated CRC in AOM/ 
DSS-treated Nrf2 KO and WT male mice. 
2. Materials and methods 
2.1. Chemicals 
AOM (Cat no A5486) was purchased from Sigma-Aldrich (St. Louis, 
MO, USA) and stored at − 20 ◦C. AOM stock solution was prepared after 
dissolving of 10 mg AOM in 10 mL Phosphate-buffered saline (PBS), pH 
7.4 (Cat no 10010-023, Gibco BRL, Gaithersburg, MD, USA). DSS 
(36,000–50,000 M.W, MP grade, Cat no 160110) was purchased from 
MP Biomedicals (Aurora, OH, USA) and stored at room temperature. 
2.5% DSS solution was prepared after dissolving of 25 g DSS into 1 L 
water. E2 (Cat no E8876) was purchased from Sigma-Aldrich (St. Louis, 
MO, USA) and stored at room temperature. E2 solution was prepared 
after dissolving in olive oil (Cat no O1514, Sigma-Aldrich, St. Louis, MO, 
USA). 
2.2. Animals and genotyping 
Heterozygous Nrf2 KO (Nrf2+/− ) mice in a C57BL6/129SV back-
ground [34] were kindly provided by Prof. Y-J Surh. WT (Nrf2+/+) and 
homozygous Nrf2 KO (Nrf2− /− ) mice were obtained by crossing the Nrf2 
heterozygous (Nrf2+/− ) mice (Fig. 1A). The mice were housed in cages 
at 23 ◦C with a 12/12-hour light/dark cycle under specific pathogen-free 
conditions. Genomic DNA (gDNA) obtained using DNeasy® Blood & 
Tissue Kit (Qiagen, Gmbh, Hilden, Germany) was used as the template 
DNA (listed in Table 1) and visualized under a ChemiDoc™ Imaging 
System (Bio-Rad Laboratories, Inc.) (Fig. 1B). All animal procedures 
were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Seoul National University Bundang Hospital (BA1705- 
223/043-01) and performed in accordance with the ARRIVE (Animals 
Research: Reporting In Vivo Experiments) protocol. 
2.3. Experimental design 
WT and Nrf2 KO male mice were randomized into the following 
three groups each. Group 1: WT control mice, Group 2: AOM/DSS- 
treated WT mice, Group 3: AOM/DSS-treated WT mice administrated 
with E2, Group 4: Nrf2 KO control mice, Group 5: AOM/DSS-treated 
Nrf2 KO mice, and Group 6: AOM/DSS-treated Nrf2 KO mice adminis-
trated with E2. The number of mice of each group was 9–12. For the 
induction of colitis, 2.5% (w/v) DSS was supplied in the drinking water 
for 7 days, one week following the injection of AOM (10 mg/kg) counted 
as Day 0 [35]. E2 was dissolved in olive oil, and administered once daily 
as an intraperitoneal injection for 7 days (E2-supplemented mice), while 
olive oil was utilized on all other groups. The animals were euthanized 
by CO2 asphyxiation at week 2 and 16 after AOM injection (Fig. 1C). 
2.4. Evaluation of clinical symptoms 
Clinical symptoms were evaluated using the disease activity index 
(DAI), which includes loss of body weight, stool characterization, and 
hematochezia [36,37]. The DAI was scored by two researchers in a 
blinded manner. 
2.5. Enumeration of lesions 
The colons were opened longitudinally, and stool was washed out 
with phosphate-buffered saline (PBS). The length of the colon was 
measured from the cecum to the rectum using a ruler. Polypoid lesions 
with a diameter ≤2 mm or >2 mm were independently counted by two 
researchers in a blinded manner [36,37]. 
2.6. Tissue processing and histopathology 
The extracted colon was divided into proximal and distal portions. 
The proximal colon up to 1.5 cm from the ileocecal valve, the rectum up 
to 1.5 cm from the anal verge, and colonic segments containing any 
gross polyps were fixed with phosphate-buffered formalin and 
embedded in paraffin. The sections (5 mm) were stained with hema-
toxylin and eosin (H&E). The classification of adenoma and adenocar-
cinoma, and the specification of the depth of adenocarcinoma invasion 
into the colonic tissues as mucosal or submucosal invasion was per-
formed in a blinded manner [38]. The histological severity was assessed 
using a microscopic damage score reflecting colonic epithelial damage 
and depth of inflammatory cell infiltration [39]. 
2.7. Measurement of inflammatory cytokines 
The level of myeloperoxidase (MPO), IL-6, and IL-1β in the colonic 
tissues was measured using a mouse MPO enzyme linked immunosor-
bent assay (ELISA) kit (HK210, Hycult Biotechnology, The Netherlands), 
a mouse IL-6 Quantikine ELISA kit (R&D Systems Inc., Minneapolis, 
MN), and a mouse IL-1β/IL-1F2 Quantikine ELISA kit (R&D Systems 
Inc., Minneapolis, MN), respectively, according to the manufacturer’s 
instructions. All assays were performed in triplicate. 
2.8. Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA was extracted from the colon tissues using TRIzol® re-
agent (Invitrogen, Carlsbad, CA, USA). For qRT-PCR, 2 µg of total RNA 
was reverse transcribed using High Capacity cDNA Reverse Transcrip-
tion kit according to the manufacturer’s instructions (Applied Bio-
systems, Foster City, CA, USA). The cDNA was used to perform qRT-PCR 
using specific primers (listed in Table 1) in a ViiA7 instrument (Applied 
Biosystems, Foster City, CA, USA). The expression levels were 
Table 1 
List of oligonucleotide sequence and their characteristics.  
Gene Sequence (5′→3′) Purpose 
Nrf2 WT F: GGA ATG GAA AAT AGC TCC TGC C 
R: GCC TGA GAG CTG TAG GCC 
Genotyping 
Nrf2 KO R: GGG TTT TCC CAG TCA CGA Genotyping 
iNOS F: TGG TGG TGA CAA GCA CAT TT 
R: AAG GCC AAA CAC AGC ATA CC 
qRT-PCR 
TNF-α F: ACG GCA TGG ATC TCA AAG AC 
R: GTG GGT GAG GAG CAC GTA GT 
qRT-PCR 
NQO1 F: GCG AGA AGA GCC CTG ATT GTA CTG 
R: TCT CAA ACC AGC CTT TCA GAA TGG 
qRT-PCR 
HO-1 F: CCT CAC TGG CAG GAA ATC ATC 
R: CCT CGT GGA GAC GCT TTA CAT A 
qRT-PCR 
GAPDH F: TTC ACC ACC ATG GAG AAG GC 
R: GGC ATG GAC TGT GGT CAT GA 
qRT-PCR 
Nrf2, nuclear factor erythroid-derived 2-related factor 2; WT, wild type; KO, 
knockout; F, forward; R, reverse; iNOS, inducible nitric oxide synthase; TNF-α, 
tumor necrosis factor-alpha; NQO1, NAD(P)H dehydrogenase (quinone) 1; HO- 
1, heme oxygenase 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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normalized to that of GAPDH. 
2.9. Western blot analysis 
Colon tissue was lysed with RIPA buffer (Cell Signaling Technology, 
Beverly, MA, USA) containing protease and phosphatase inhibitors. 
Total protein was separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene 
difluoride (PVDF) membrane (Cat no 10600023, GE Healthcare Life 
science, Germany). Western blot analysis was performed with specific 
primary antibodies (listed in Table 2). The signals were then detected 
with an enhanced chemiluminescence (ECL) kit (GE Healthcare Bio-
sciences, UK). The band intensity was quantified by densitometric 
analysis using the ImageJ software (National Institutes of Health, 
Bethesda, MD). 
2.10. Statistical analysis 
Data are expressed as the mean ± standard error of mean (SEM). 
Statistical significance was examined with the Mann-Whitney test or 
Fisher’s exact test. P < 0.05 was considered statistically significance. All 
statistical analyses were conducted using GraphPad Prism (GraphPad) 
and SPSS version 18.0 (SPSS Inc.). 
3. Results 
3.1. Nrf2 determines the differential effect of E2 on DAI score during 
inflammation and tumorigenesis. 
DAI score parameters including body weight changes, stool consis-
tency, and hematochezia were measured every week (Fig. 2A and D). 
Loss of body weight is a sensitive indicator of the severity of colitis [40]. 
The AOM/DSS-induced reduction in body weight was not reversed by E2 
treatment in both WT and Nrf2 KO mice at week 2 or 16 (Fig. 2B and 2C). 
There was no significant difference in the DAI score between control and 
the E2 supplemented groups in both WT and Nrf2 KO mice (Fig. 2E). 
However, the inhibitory effect of E2 on DAI score was observed at week 
16, which was stronger in the Nrf2 KO group than in the the WT group 
(Fig. 2F), although the loss of body weight was significant in Nrf2 KO 
compared to the WT (Fig. 2C) at week 16. 
3.2. Nrf2 is critical for E2-induced suppression of colitis at week 2. 
Representative histopathological images (Fig. 3A) and microscopic 
damage scores (Fig. 3B) showed that the E2-treated AOM/DSS group 
had significantly less inflammatory cell infiltration and milder cryptic 
damage than AOM/DSS group in both WT and Nrf2 KO mice. This 
inhibitory effect of E2 was significantly weaker in the Nrf2 KO group 
than in the WT group (Fig. 3B). Next, we performed ELISA to measure 
the level of MPO. At week 2, the AOM/DSS-mediated enhancement of 
the MPO level was significantly decreased following E2 administration, 
both in the WT and Nrf2 KO group. However, the inhibitory effect of E2 
in the Nrf2 KO group showed only a tendency to decrease compared 
with WT, but there was no significance (Fig. 3C). These results indicate 
that the anti-inflammatory effect of estrogen is mediated through Nrf2 at 
the colitis stage. 
3.3. E2 strongly attenuates colitis-associated tumorigenesis in Nrf2 KO 
mice at week 16 
The tumors that developed in the distal region of colon following 
AOM/DSS treatment were strongly diminished following E2 adminis-
tration regardless of the polyp size. However, the anti-tumorigenic effect 
of E2 was more significant in the Nrf2 KO group compared to the WT 
group (Fig. 4A). Representative histopathological images are shown in 
Fig. 4B. Table 3 summarizes the incidence of microscopic colonic neo-
plasms. Similar to tumor count results, AOM/DSS-mediated increment 
in tumor incidence rate, specifically that of mucosal invasive adeno-
carcinoma, at distal region of colon was sharply decreased by E2 sup-
plementation in Nrf2 KO, but not in WT mice (Fig. 4C). These results 
indicate that the anti-tumorigenic effect of estrogen is more powerful in 
the absence of Nrf2. 
3.4. Nrf2 deficiency enhances the inhibitory effect of E2 on 
proinflammatory gene expression at week 16 
At week 2, AOM/DSS-induced mRNA expression of iNOS and TNF-α 
decreased following E2 administration both in WT and Nrf2 KO mice 
(Fig. 5A). Next, we performed ELISA to measure the concentration of the 
proinflammatory cytokine IL-1β. The elevation in the colonic IL-1β level 
following AOM/DSS treatment was significantly inhibited by E2 
administration in both WT and Nrf2 KO mice to a similar extent 
(Fig. 5B). Surprisingly, the AOM/DSS-induced IL-1β level was strongly 
enhanced in the Nrf2 KO mice compared to the WT mice (Fig. 5B). 
Furthermore, the inhibitory effect of E2 on TNF-α and IL-1β production 
by AOM/DSS treatment was significantly weakened in Nrf2 KO 
compared with WT (Fig. 5A and 5B). At week 16, the elevated mRNA 
expression of iNOS and TNF-α by AOM/DSS treatment was significantly 
decreased in the Nrf2 KO group and further inhibited by E2 treatment 
(Fig. 5C). Furthermore, AOM/DSS-induced IL-1β level was significantly 
reduced by E2 treatment in Nrf2 KO group, but not in the WT group. 
(Fig. 5D). 
3.5. Effect of E2 on Nrf2-mediated antioxidant enzyme genes during 
colitis and carcinogenesis in Nrf2 KO mice at week 2 and 16 
We measured mRNA expression of the antioxidant enzyme genes 
using qRT-PCR at week 2 and week 16. At week 2, mRNA expression of 
NQO1 and HO-1 was strongly increased by E2 administration in WT, but 
not in Nrf2 KO mice (Fig. 6A). At week 16, AOM/DSS-induced NQO1 
and HO-1 mRNA levels were significantly decreased by E2 supplemen-
tation in WT mice (Fig. 6B). However, in the Nrf2 KO group, the AOM/ 
DSS-induced mRNA expression was significantly decreased compared to 
the WT group and further inhibited following E2 supplementation 
(Fig. 6B). 
We previously investigated the molecular link between Nrf2 and 
estrogen signaling. In normal colonic epithelial CCD841CoN cells, ERβ 
expression was increased by E2 treatment, but not ERα [32]. The 
inhibitory effect of E2 on TNF-α-induced COX-2 or iNOS expression was 
removed by ERβ specific antagonist PHTPP (4-(2-phenyl-5,7-bis(tri-
fluoromethyl) pyrazolo(1,5-a)pyrimidin-3-yl)phenol) treatment in 
CCD841CoN cells [32] and WT MEFs [33]. However, in Nrf2 KO MEFs, 
TNF-α-induced iNOS expression was not changed by E2 with or without 
PHTPP treatment [33]. Furthermore, in ovariectomized (OVX) female 
mice, during carcinogenesis stage at weeks 16, AOM/DSS-induced 
decrement of ERβ protein expression was increased by E2 supplemen-
tation, but not ERα [41]. In this regard, to determine the molecular link 
between Nrf2 and estrogen signaling, we analyzed the protein expres-
sion of estrogen receptor beta (ERβ), which is a member of the nuclear 
steroid receptor superfamily. At week 16 of cancer development, AOM/ 
DSS-mediated decrease in ERβ protein expression was not rescued by E2 
treatment in the WT group (Fig. 6C). Interestingly, E2-mediated induc-
tion of ERβ protein expression was stronger in Nrf2 KO mice than in WT 
Table 2 
List of antibodies and their characteristics.  
Antigen Antibody Dilution 
ERβ Abcam (ab3576) WB (1:500) 
β-Actin Santa Cruz Biotechnology (sc-47778) WB (1:1000) 
WB, Western blot; ERβ, estrogen receptor beta; β-Actin, beta-actin. 
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Fig. 2. Effect of E2 via Nrf2 on phenotypic changes of colitis. (A-C) Body weight during the experimental period (A), at week 2 (B), and at week 16 (C). (D-F) DAI 
score during experimental period (D), at week 2 (E), and at week 16 (F). Con, male control mice; AOM/DSS, AOM and DSS-treated male mice; AOM/DSS/E2, AOM, 
DSS, and 17β-estradiol-treated male mice. *p < 0.05 between two groups. WT, wild-type; KO, homogeneous knockout; AOM, azoxymethane; DSS, dextran sodium 
sulfate; E2, 17β-estradiol; DAI, disease activity index. 
Fig. 3. Inhibitory effect of E2 via Nrf2 on the colitis indices. (A) Weakened inhibitory effect of E2 on AOM/DSS-treated enhanced inflammatory cell infiltration in 
Nrf2 KO male mice. Representative H&E staining images of colon tissues at week 2. Magnification, ×100. The crypt within colon tissues was normal in WT and Nrf2 
KO control mice. However, crypt loss and strong inflammatory cell infiltration within the colon tissues (white arrow) were observed in both AOM/DSS-treated WT 
and Nrf2 KO male mice. In the WT group, AOM/DSS-induced histologic damage was inhibited by E2 supplementation, with only mild erosion (yellow arrow) 
observable. However, the inhibition was weakened in Nrf2 KO mice than in WT. (B) The inhibitory effect of E2 on the microscopic damage score was weakened in 
AOM/DSS-induced Nrf2 KO male mice. (C) The AOM/DSS-mediated increased MPO level in colonic tissues was inhibited following administration of E2 in both WT 
and Nrf2 KO male mice. Con, male control mice; AOM/DSS, AOM and DSS-treated male mice; AOM/DSS/E2, AOM, DSS, and 17β-estradiol-treated male mice. *p <
0.05 for comparison between two groups. WT, wild-type; KO, homogeneous knockout; AOM, azoxymethane; DSS, dextran sodium sulfate; E2, 17β-estradiol; MPO, 
myeloperoxidase. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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mice (Fig. 6C). 
4. Discussion 
Our results showed strong attenuation of the disease activity index 
and colon tissue damage by E2 in WT mice at week 2 and to a lesser 
extent in the Nrf2 KO male mice. However, at week 16, E2 significantly 
diminished AOM/DSS-induced adenoma/cancer incidence in the distal 
colon in the Nrf2 KO group, but not in the WT, suggesting differential 
roles of Nrf2 during inflammation and carcinogenesis stages. In 
Fig. 4. Effect of E2 via Nrf2 on the colon tumor multiplicity at weeks 16. (A) Average tumor numbers and size distribution in the proximal, distal, and whole colon in 
each group sacrificed at week 16 following AOM injection. (B) Representative H&E staining images at week 16. (C) Quantification of adenoma/adenocarcinoma 
incidence and invasion in each group by microscopic evaluation of the colonic tissues at the carcinogenesis step (at week 16). Con, male control mice; AOM/DSS, 
AOM and DSS-treated male mice; AOM/DSS/E2, AOM, DSS, and 17β-estradiol-treated male mice. *p < 0.05 for Con. vs. AOM/DSS; †, p < 0.05 for AOM/DSS vs. 
AOM/DSS/E2; ‡, p < 0.05 for WT vs. Nrf2 KO. WT, wild-type; KO, homogeneous knockout; AOM, azoxymethane; DSS, dextran sodium sulfate; E2, 17β-estradiol. 
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addition, the anti-cancer effect of estrogen was stronger in the absence 
of Nrf2 due to the nonexistence of Nrf2-induced cancer promoting 
effects. 
The Nrf2 signaling pathway plays a pivotal role in the regulation of 
inflammation and oxidative stress [42–46]. It has been shown that the 
lack of Nrf2 in sickle cell disease (SCD) mice results in reduced expres-
sion of its target antioxidant proteins such as HO-1, leading to increased 
levels of ROS and proinflammatory cytokines [47]. A study using peri-
toneal macrophages prepared from WT and Nrf2 KO mice showed that 
the anti-inflammatory effects of phytochemicals such as phenethyl iso-
thiocyanate and curcumin is mediated through Nrf2 [42]. According to 
the report, iNOS protein expression is more strongly inhibited by phe-
nethyl isothiocyanate and curcumin treatment in WT macrophages than 
in Nrf2 KO macrophages [42]. Several studies have suggested that Nrf2 
KO mice are more susceptible to inflammatory disorders [48,49]. 
Furthermore, Nrf2 deficiency also affects body weight regulation. Ac-
cording to the study by Pi et al., the body weight of adult Nrf2 KO mice is 
lower compared to that of WT mice under normal chow diet [50]. Nrf2 
deficiency prevents high fat diet-induced weight gain and obesity due to 
a decrease in the expression of peroxisome proliferator-activated re-
ceptor γ [50]. Similarly, in the present study, the body weight of Nrf2 KO 
mice was significantly lower compared to that of the WT mice at week 
16 after AOM/DSS treatment. Colitis symptoms such as disease activity 
index and colon tissue damage were more strongly inhibited by E2 in WT 
mice than in Nrf2 KO mice. Although body weight loss is a sensitive 
indicator of the severity of colitis, it did not show consistent results with 
DAI score on the inhibitory effect of E2. At the molecular level, the basal 
mRNA expression level of the proinflammatory mediator, iNOS, was 
strongly elevated in Nrf2 KO mice compared to WT mice. AOM/DSS- 
induced colonic IL-1β concentration was strongly enhanced in the 
Nrf2 KO group than in the WT group. We previously reported that the 
anti-inflammatory effect of E2 at the molecular levels was weakened in 
TNF-α-stimulated Nrf2 KO MEFs than in WT MEFs [33]. We believe that 
these results are complicated by the fact that multi-signal state system 
operates in vivo in animals. 
Unlike its cytoprotective effect during inflammation, Nrf2 is 
involved in maintaining proliferation and invasion of cancer cells by 
metabolic reprogramming, repression of cancer cell apoptosis, and 
enhancement of self-renewal capacity of cancer stem cells during the 
cancerous stages. More importantly, aberrant activation of Nrf2 is 
associated with chemoresistance of cancer cells and poor prognosis 
(reviewed in [51]). Furthermore, we previously showed the regulatory 
mechanism of estrogen during colon cancer progression in terms of Nrf2 
using the AOM/DSS-treated male mice model [31]. Nrf2 and its-related 
antioxidant enzymes were highly expressed in the AOM/DSS-treated 
group, which developed cancer [31]. Therefore, we expected that 
AOM/DSS-induced carcinogenesis would be less severe in Nrf2 KO mice 
than in WT mice. Although no alleviation in tumor incidence was 
observed in the Nrf2 KO, the mRNA and protein levels of proin-
flammatory mediators were significantly lower in the AOM/DSS-treated 
Nrf2 KO mice than in the WT mice. Unexpectedly, when E2 was 
administered, its anti-tumorigenic effect was stronger in the AOM/DSS- 
treated Nrf2 KO group than in WT. Interestingly, the expression of ERβ 
protein increased more strongly in the AOM/DSS-treated Nrf2 KO group 
Table 3 
Incidence of adenoma and cancer in the colon.   
WT male KO male WT vs KO 
Con 
(n = 9) 
AOM/DSS   
(n = 10) 
AOM/DSS/E2  
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(n = 10) 
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Values are expressed as the % (number/subtotal). WT, wild-type; KO, knockout; Con, control; AOM, azoxymethane; DSS, dextran sodium sulfate; E2, 17β-estradiol. a, 
control vs AOM/DSS; b, AOM/DSS vs AOM/DSS/E2; c, WT vs KO for AOM/DSS; d, WT vs KO for AOM/DSS/E2 (by Fisher’s exact test for a 2 × 2 table); red color, 
statistical significance (p < 0.05). 
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supplemented with E2 than in WT. These data suggest that in the 
absence of Nrf2, the anti-tumorigenic effect of estrogen may be medi-
ated through other pathways such as ERβ-related pathway. 
It is clear that there exists a compensatory mechanism of estrogen 
signaling which is independent on Nrf2. Estrogen receptors have both 
genomic and non-genomic pathways in response to estrogen signaling 
[52]. Non-genomic pathways are common to sex steroid hormones and 
are generally associated with the activation of various protein kinase 
cascades such as the mitogen-activated protein kinase (MAPK), c-Jun N- 
terminal kinase (JNK), and extracellular-signal related kinase (ERK)1/2 
[53,54]. According to a recent report, ERK1/2-dependent ELK-1 acti-
vation upregulates 15-Hydroxyprostaglandin dehydrogenase (15- 
PGDH) in the presence of 15-deoxy-Δ12, 14-prostaglandin J2 (15d- 
PGJ2), which is one of the terminal products of cyclooxygenase-2 (COX- 
2), in the MDA-MB-231 cells [55]. Several studies have demonstrated 
the tumor suppressor function of 15-PGDH [56,57]. The expression of 
15-PGDH is significantly reduced in various human malignances, such as 
colon, lung, and gastric cancers compared to normal tissues [58,59]. We 
selected and tested 15-PGDH as another target of estrogen in addition to 
ERβ. However, the level of 15-PGDH which decreased following AOM/ 
DSS treatment was not rescued by estrogen treatment (data not shown). 
To overcome the limitation of our present study, we intend to perform 
further animal experiments in the future using an ERβ antagonist to 
clarify the compensatory mechanism of estrogen through ERβ in the 
absence of Nrf2. 
We previously reported that Nrf2 plays dual roles in colitis and 
Fig. 5. Inhibitory effect of E2 via Nrf2 on the pro-inflammatory genes in colon tissues at weeks 2 (A and B) and 16 (C and D). (A and C) mRNA expression of iNOS and 
TNF-α by qRT-PCR analysis at weeks 2 (A) and 16 (C). (B and D) IL-1β level measurement by ELISA in colon tissues at weeks 2 (B) and 16 (D). Con, male control mice; 
AOM/DSS, AOM and DSS-treated male mice; AOM/DSS/E2, AOM, DSS, and 17β-estradiol-treated male mice. * p < 0.05 for comparison between two groups. WT, 
wild-type; KO, homogeneous knockout; AOM, azoxymethane; DSS, dextran sodium sulfate; E2, 17β-estradiol; iNOS, inducible nitric oxide synthase; TNF-α, tumor 
necrosis factor-alpha; IL-1β, interleukin 1 beta. 
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cancer progression, and has sex differences [31]. In this study, using 
Nrf2 KO male mice, we verified estrogen-mediated effects through Nrf2. 
Based on the present and previously published [31–33,41,60–63] data, 
the regulatory mechanism of estrogen in colitis and colitis-associated 
CRC in WT and Nrf2 KO mice is proposed to be as follows (Fig. 7). At 
week 2, in the presence of Nrf2, estrogen signals through G protein 
coupled receptor (GPCR) to induce Nrf2 activation [31,60,61] leading to 
the subsequent expression of various Nrf2 target genes such as NQO1 
and HO-1. Nrf2 inhibits NF-κB pathway and ROS production through 
upregulation of antioxidant enzymes [31–33]. Eventually, estrogen 
ameliorates the severity of colitis indicated as DAI score and microscopic 
damage score through Nrf2 activation (left panel at week 2). In contrast, 
in the absence of Nrf2, estrogen does not effectively inhibit colitis (right 
panel at week 2) [33]. After unsuccessful elimination of precancerous 
cells, inflammation progresses to cancer [62]. At week 16, in the 
presence of Nrf2, Nrf2 promotes tumor progression by activation of 
antioxidant enzymes [31,41]. Estrogen signaling through membrane 
estrogen receptor beta (mERβ) [41,63] inhibits antioxidant and proin-
flammatory enzymes. The inhibitory effect of E2 in the presence of Nrf2 
is not sufficient to inhibit tumor development in the distal colon (left 
panel at week 16). In contrast, in the absence of Nrf2, estrogen strongly 
inhibits tumor development in the distal colon through Nrf2- 
independent ERβ-related signaling pathway (right panel at week 16). 
In conclusion, our study shows that estrogen further inhibits CRC by 
upregulating other ERβ-related pathways in the absence of Nrf2. These 
findings may provide a new therapeutic strategy in which estrogen in-
hibits the progression of colitis-associated CRC depending on the level of 
Nrf2, and suggest that ERβ may be a useful target for gene therapy in 
CRC patients. 
Fig. 6. Effect of E2 on mRNA and protein expression of Nrf2-mediated antioxidant enzyme genes and ERβ at weeks 2 (A) and 16 (B and C). (A and B) mRNA 
expression of antioxidant enzyme genes, NQO1 and HO-1, by qRT-PCR analysis at weeks 2 (A) and 16 (B). (C) ERβ protein (60 µg of proteins) expression by western 
blot analysis at week 16. Con, male control mice; AOM/DSS, AOM and DSS-treated male mice; AOM/DSS/E2, AOM, DSS, and 17β-estradiol-treated male mice. *p <
0.05 for comparison between two groups. WT, wild-type; KO, homogeneous knockout; AOM, azoxymethane; DSS, dextran sodium sulfate; E2, 17β-estradiol; NQO1, 
NAD(P)H dehydrogenase (quinone) 1; HO-1, heme oxygenase 1; ERβ, estrogen receptor beta. 
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Fig. 7. Proposed regulatory mechanism of estrogen through Nrf2 in colitis-associated CRC at week 2 (A) and week 16 (B). (A) At week 2, in the presence of Nrf2, 
estrogen signaling through G protein coupled receptor (GPCR) induces Nrf2 activation and subsequently induces the Nrf2 target genes such as NQO1 and HO-1. Nrf2 
inhibits NF-κB and ROS through the antioxidant enzymes. Eventually, colitis indices such as DAI score and microscopic damage score mediated by Nrf2 activation are 
inhibited by estrogen (left panel). In contrast, in the absence of Nrf2, estrogen does not effectively inhibit colitis (right panel). (B) At week 16, in the presence of Nrf2, 
Nrf2 promotes tumor progression by activation of antioxidant enzymes. Estrogen signaling through the membrane estrogen receptor beta (ERβ) inhibits antioxidant 
enzymes and proinflammatory enzymes. The inhibitory effect of E2 in the presence of Nrf2 is not sufficient to inhibit tumor development at the distal colon (left 
panel). In contrast, in the absence of Nrf2, estrogen strongly inhibits tumor development at distal colon through Nrf2-independent ERβ-related signaling pathway 
(right panel). 
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